Vanesa G Martinez1, Lorraine O'Driscoll2. 1. School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland. 2. School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland. lodrisc@tcd.ie.
Abstract
BACKGROUND: Neuromedin U (NmU) belongs to the neuromedin family, comprising a series of neuropeptides involved in the gut-brain axis and including neuromedins B and C (bombesin-like), K (neurokinin B), L (neurokinin A or neurotensin), N, S, and U. CONTENT: Although initially isolated from porcine spinal cord on the basis of their ability to induce uterine smooth muscle contraction, these peptides have now been found to be expressed in several different tissues and have been ascribed numerous functions, from appetite regulation and energy balance control to muscle contraction and tumor progression. NmU has been detected in several species to date, particularly in mammals (pig, rat, rabbit, dog, guinea pig, human), but also in amphibian, avian, and fish species. The NmU sequence is highly conserved across different species, indicating that this peptide is ancient and plays an important biological role. Here, we summarize the main structural and functional characteristics of NmU and describe its many roles, highlighting the jack-of-all-trades nature of this neuropeptide. SUMMARY: NmU involvement in key processes has outlined the possibility that this neuropeptide could be a novel target for the treatment of obesity and cancer, among other disorders. Although the potential for NmU as a therapeutic target is obvious, the multiple functions of this molecule should be taken into account when designing an approach to targeting NmU and/or its receptors.
BACKGROUND:Neuromedin U (NmU) belongs to the neuromedin family, comprising a series of neuropeptides involved in the gut-brain axis and including neuromedins B and C (bombesin-like), K (neurokinin B), L (neurokinin A or neurotensin), N, S, and U. CONTENT: Although initially isolated from porcine spinal cord on the basis of their ability to induce uterine smooth muscle contraction, these peptides have now been found to be expressed in several different tissues and have been ascribed numerous functions, from appetite regulation and energy balance control to muscle contraction and tumor progression. NmU has been detected in several species to date, particularly in mammals (pig, rat, rabbit, dog, guinea pig, human), but also in amphibian, avian, and fish species. The NmU sequence is highly conserved across different species, indicating that this peptide is ancient and plays an important biological role. Here, we summarize the main structural and functional characteristics of NmU and describe its many roles, highlighting the jack-of-all-trades nature of this neuropeptide. SUMMARY:NmU involvement in key processes has outlined the possibility that this neuropeptide could be a novel target for the treatment of obesity and cancer, among other disorders. Although the potential for NmU as a therapeutic target is obvious, the multiple functions of this molecule should be taken into account when designing an approach to targeting NmU and/or its receptors.
Authors: Heping Xu; Jiarui Ding; Caroline B M Porter; Antonia Wallrapp; Marcin Tabaka; Sai Ma; Shujie Fu; Xuanxuan Guo; Samantha J Riesenfeld; Chienwen Su; Danielle Dionne; Lan T Nguyen; Ariel Lefkovith; Orr Ashenberg; Patrick R Burkett; Hai Ning Shi; Orit Rozenblatt-Rosen; Daniel B Graham; Vijay K Kuchroo; Aviv Regev; Ramnik J Xavier Journal: Immunity Date: 2019-10-15 Impact factor: 31.745
Authors: An De Prins; Charlotte Martin; Yannick Van Wanseele; Csaba Tömböly; Dirk Tourwé; Vicky Caveliers; Birgitte Holst; Ann Van Eeckhaut; Mette M Rosenkilde; Ilse Smolders; Steven Ballet Journal: ACS Med Chem Lett Date: 2018-04-23 Impact factor: 4.345
Authors: T Kaisho; H Nagai; T Asakawa; N Suzuki; H Fujita; K Matsumiya; N Nishizawa; Y Kanematsu-Yamaki; K Dote; J-I Sakamoto; T Asami; S Takekawa Journal: Int J Obes (Lond) Date: 2017-07-31 Impact factor: 5.095
Authors: Aneta Piwowarczyk-Nowak; Artur Pałasz; Aleksandra Suszka-Świtek; Alessandra Della Vecchia; Aniela Grajoszek; Marek Krzystanek; John J Worthington Journal: Pharmacol Rep Date: 2022-06-02 Impact factor: 3.919
Authors: Annalisa Marotta; Fabrizia Noro; Roberta Parisi; Alessandro Gialluisi; Alfonsina Tirozzi; Amalia De Curtis; Simona Costanzo; Augusto Di Castelnuovo; Chiara Cerletti; Maria Benedetta Donati; Giovanni de Gaetano; Licia Iacoviello; Benedetta Izzi; Francesco Gianfagna Journal: Epigenetics Date: 2021-01-04 Impact factor: 4.528